Friday, July 10, 2026

pharma · Ovarian Neoplasms · Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer

TESARO Bio Netherlands

TESARO Bio Netherlands clinical programs — 1 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

EU HQ
EMA registrant Type
Company details
Status
Public
HQ
EU
Programs
6
Drugs
23
Patents
0
Intelligence · Clinical Programs

TESARO Bio Netherlands projects

1 ClinicalTrials.gov programs sponsored by TESARO Bio Netherlands.

TESARO Bio Netherlands has 1 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 213357

    TESARO Bio Netherlands B.V.

    Ovarian Neoplasms

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does TESARO Bio Netherlands have?

1 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.